[CAS NO. 1507370-20-8] BC-1215
PRODUCTS SPECIFICATIONS [1507370-20-8]
DESCRIPTION [1507370-20-8]
Overview
| MDL | MFCD28118991 |
|---|---|
| Molecular Weight | 394.51 |
| Molecular Formula | C26H26N4 |
| SMILES | C1(CNCCNCC2=CC=C(C3=NC=CC=C3)C=C2)=CC=C(C4=NC=CC=C4)C=C1 |
1 Publications Citing Use of MCE
Summary
BC-1215 is a F-box protein 3 (Fbxo3) inhibitor. BC-1215 works by antagonizing of Fbxo3 on TRAF cytokine signaling and exhibits a low IC 50 in vitro. BC-1215 can be used for the research of inflammation [1] .
In Vitro
BC-1215 (0, 0.4, 2, 10, 50 µg/mL; 16 h, 18 h and 24 h) inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1-6 [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | Murine lung epithellal (MLE) cells, PBMC cells and U937 cells |
| Concentration: | 0, 0.4, 2, 10, 50 µg/mL |
| Incubation Time: | 6 h, 18 h and 24 h |
| Result: | Decreased TRAF protein and inhibited a broad spectrum of Th1 panel cytokines. |
In Vivo
BC-1215 (i.p.; 100 μg) reduces bacterial-induced inflammationa [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Cecal ligation and puncture (CLP)-induced sepsis model [1] |
| Dosage: | 100 μg |
| Administration: | i.p. |
| Result: | Significantly attenuated CLP-induced secretion of all three circulating pro-inflammatory cytokines and decreased bacterial counts in the CLP model. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 12.5 mg/mL ( 31.68 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5348 mL | 12.6740 mL | 25.3479 mL |
| 5 mM | 0.5070 mL | 2.5348 mL | 5.0696 mL |
| 10 mM | 0.2535 mL | 1.2674 mL | 2.5348 mL |
